CROSS COUNTRY HEALTHCARE INC (CCRN) Stock Fundamental Analysis
NASDAQ:CCRN - Nasdaq - US2274831047 - Common Stock - Currency: USD
Overall CCRN gets a fundamental rating of 4 out of 10. We evaluated CCRN against 103 industry peers in the Health Care Providers & Services industry. While CCRN has a great health rating, there are worries on its profitability. CCRN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CCRN had positive earnings in the past year.
CCRN had a positive operating cash flow in the past year.
In multiple years CCRN reported negative net income over the last 5 years.
Of the past 5 years CCRN 4 years had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -3.08%, CCRN is doing worse than 60.19% of the companies in the same industry.
The Return On Equity of CCRN (-4.24%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.08% | ||
| ROE | -4.24% | ||
| ROIC | N/A |
ROA(3y)9.37%
ROA(5y)8.5%
ROE(3y)17.7%
ROE(5y)17.81%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CCRN's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 20.32%, CCRN is doing worse than 60.19% of the companies in the same industry.
CCRN's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for CCRN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 20.32% |
OM growth 3Y-77.97%
OM growth 5Y-33.84%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.01%
GM growth 5Y-3.83%
2. Health
2.1 Basic Checks
CCRN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CCRN has been reduced compared to 1 year ago.
CCRN has less shares outstanding than it did 5 years ago.
CCRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 4.63 indicates that CCRN is not in any danger for bankruptcy at the moment.
The Altman-Z score of CCRN (4.63) is better than 79.61% of its industry peers.
CCRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.63 |
ROIC/WACCN/A
WACC9.07%
2.3 Liquidity
A Current Ratio of 2.98 indicates that CCRN has no problem at all paying its short term obligations.
CCRN has a Current ratio of 2.98. This is amongst the best in the industry. CCRN outperforms 87.38% of its industry peers.
A Quick Ratio of 2.98 indicates that CCRN has no problem at all paying its short term obligations.
The Quick ratio of CCRN (2.98) is better than 87.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.98 | ||
| Quick Ratio | 2.98 |
3. Growth
3.1 Past
The earnings per share for CCRN have decreased strongly by -79.49% in the last year.
Measured over the past years, CCRN shows a very strong growth in Earnings Per Share. The EPS has been growing by 24.57% on average per year.
CCRN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -29.16%.
Measured over the past years, CCRN shows a quite strong growth in Revenue. The Revenue has been growing by 10.33% on average per year.
EPS 1Y (TTM)-79.49%
EPS 3Y-47.22%
EPS 5Y24.57%
EPS Q2Q%-68.42%
Revenue 1Y (TTM)-29.16%
Revenue growth 3Y-7.11%
Revenue growth 5Y10.33%
Sales Q2Q%-22.62%
3.2 Future
The Earnings Per Share is expected to grow by 10.79% on average over the next years. This is quite good.
The Revenue is expected to decrease by -0.05% on average over the next years.
EPS Next Y-30.71%
EPS Next 2Y4.85%
EPS Next 3Y10.79%
EPS Next 5YN/A
Revenue Next Year-11.63%
Revenue Next 2Y-3.2%
Revenue Next 3Y-0.05%
Revenue Next 5YN/A
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 37.88 indicates a quite expensive valuation of CCRN.
The rest of the industry has a similar Price/Earnings ratio as CCRN.
CCRN is valuated rather expensively when we compare the Price/Earnings ratio to 27.51, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 24.50 indicates a rather expensive valuation of CCRN.
CCRN's Price/Forward Earnings ratio is in line with the industry average.
When comparing the Price/Forward Earnings ratio of CCRN to the average of the S&P500 Index (35.58), we can say CCRN is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.88 | ||
| Fwd PE | 24.5 |
4.2 Price Multiples
CCRN's Enterprise Value to EBITDA is on the same level as the industry average.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CCRN indicates a rather cheap valuation: CCRN is cheaper than 97.09% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.57 | ||
| EV/EBITDA | 24.58 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)1.54
EPS Next 2Y4.85%
EPS Next 3Y10.79%
5. Dividend
5.1 Amount
CCRN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:CCRN (7/15/2025, 10:35:43 AM)
12.12
+0.04 (+0.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners99.95%
Inst Owner Change0%
Ins Owners5.71%
Ins Owner Change-0.22%
Market Cap397.29M
Analysts52.31
Price Target18.44 (52.15%)
Short Float %5.79%
Short Ratio7.35
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-30.26%
Min EPS beat(2)-66.11%
Max EPS beat(2)5.59%
EPS beat(4)2
Avg EPS beat(4)-16.07%
Min EPS beat(4)-66.11%
Max EPS beat(4)22.23%
EPS beat(8)5
Avg EPS beat(8)-5.82%
EPS beat(12)9
Avg EPS beat(12)-0.39%
EPS beat(16)13
Avg EPS beat(16)7.65%
Revenue beat(2)0
Avg Revenue beat(2)-3.28%
Min Revenue beat(2)-5.84%
Max Revenue beat(2)-0.73%
Revenue beat(4)0
Avg Revenue beat(4)-1.87%
Min Revenue beat(4)-5.84%
Max Revenue beat(4)-0.41%
Revenue beat(8)1
Avg Revenue beat(8)-1.29%
Revenue beat(12)4
Avg Revenue beat(12)-0.29%
Revenue beat(16)8
Avg Revenue beat(16)1.65%
PT rev (1m)0%
PT rev (3m)-2.83%
EPS NQ rev (1m)-5.91%
EPS NQ rev (3m)-38.35%
EPS NY rev (1m)-15.08%
EPS NY rev (3m)-23.84%
Revenue NQ rev (1m)-0.22%
Revenue NQ rev (3m)-4.71%
Revenue NY rev (1m)-1.47%
Revenue NY rev (3m)-4.81%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.88 | ||
| Fwd PE | 24.5 | ||
| P/S | 0.32 | ||
| P/FCF | 3.57 | ||
| P/OCF | 3.32 | ||
| P/B | 0.95 | ||
| P/tB | 1.63 | ||
| EV/EBITDA | 24.58 |
EPS(TTM)0.32
EY2.64%
EPS(NY)0.49
Fwd EY4.08%
FCF(TTM)3.4
FCFY28.04%
OCF(TTM)3.65
OCFY30.15%
SpS38.38
BVpS12.76
TBVpS7.42
PEG (NY)N/A
PEG (5Y)1.54
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.08% | ||
| ROE | -4.24% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 20.32% | ||
| FCFM | 8.85% |
ROA(3y)9.37%
ROA(5y)8.5%
ROE(3y)17.7%
ROE(5y)17.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)21.31%
ROCE(5y)19.23%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-77.97%
OM growth 5Y-33.84%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.01%
GM growth 5Y-3.83%
F-Score4
Asset Turnover2.18
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 45.77% | ||
| Cap/Sales | 0.67% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 933.79% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.98 | ||
| Quick Ratio | 2.98 | ||
| Altman-Z | 4.63 |
F-Score4
WACC9.07%
ROIC/WACCN/A
Cap/Depr(3y)64.63%
Cap/Depr(5y)60.57%
Cap/Sales(3y)0.55%
Cap/Sales(5y)0.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-79.49%
EPS 3Y-47.22%
EPS 5Y24.57%
EPS Q2Q%-68.42%
EPS Next Y-30.71%
EPS Next 2Y4.85%
EPS Next 3Y10.79%
EPS Next 5YN/A
Revenue 1Y (TTM)-29.16%
Revenue growth 3Y-7.11%
Revenue growth 5Y10.33%
Sales Q2Q%-22.62%
Revenue Next Year-11.63%
Revenue Next 2Y-3.2%
Revenue Next 3Y-0.05%
Revenue Next 5YN/A
EBIT growth 1Y-106.89%
EBIT growth 3Y-79.54%
EBIT growth 5Y-27.01%
EBIT Next Year706.57%
EBIT Next 3Y126.18%
EBIT Next 5YN/A
FCF growth 1Y-44.19%
FCF growth 3YN/A
FCF growth 5Y112.02%
OCF growth 1Y-42.96%
OCF growth 3YN/A
OCF growth 5Y85.29%